AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19169651 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (PHT)
Number of subjects: 29
Study 17584551 — intervention group
Group type: EXPERIMENTAL
Intervention: Registry patients (not enrolled in the trial)
Number of subjects: 3726
Study 17584551 — intervention group
Group type: COMPARATOR
Intervention: Trial patients (ExTRACT-TIMI 25)
Number of subjects: 3726
Study 17584551 — intervention group
Group type: EXPERIMENTAL
Intervention: Registry patients (after adjusting for TIMI Risk Index)
Number of subjects: 3726
Study 17584551 — intervention group
Group type: EXPERIMENTAL
Intervention: GNI (gross national income)
Number of subjects: 3726
Study 10964731 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographer
Number of subjects: 100
Study 10964731 — intervention group
Group type: COMPARATOR
Intervention: Radiologist
Number of subjects: 100
Study 10964731 — intervention group
Group type: EXPERIMENTAL
Intervention: Both operators
Number of subjects: 100
Study 8792693 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole 30 mg
Number of subjects: 1284
Study 8792693 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole 15 mg
Number of subjects: 1284
Study 8792693 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole 20 mg
Number of subjects: 1284
Study 8792693 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1284
Study 8792693 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole 30 mg vs lansoprazole 15 mg
Number of subjects: 1284
Study 8792693 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole 20 mg vs lansoprazole 15 mg
Number of subjects: 1284
Study 8792693 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole 30 mg vs omeprazole 20 mg
Number of subjects: 1284
Study 1620832 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine (100 mg tablet)
Number of subjects: 400
Study 1620832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 6735042 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 749 RP 1 mg/kg
Number of subjects: 6
Study 6735042 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 749 RP 2 mg/kg
Number of subjects: 6
Study 6735042 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 749 RP 4 mg/kg
Number of subjects: 6
Study 6735042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30198967 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5mg ranibizumab monthly for 12 months
Number of subjects: 24
Study 29235564 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC)
Number of subjects: 126
Study 29235564 — intervention group
Group type: COMPARATOR
Intervention: No induction chemotherapy (Control)
Number of subjects: 126
Study 29235564 — intervention group
Group type: EXPERIMENTAL
Intervention: WMD with IC
Number of subjects: 126
Study 29235564 — intervention group
Group type: COMPARATOR
Intervention: Very high risk (PD, cN2/N3)
Number of subjects: 126
Study 29235564 — intervention group
Group type: COMPARATOR
Intervention: High risk (PD, cN0/N1, stage cIII)
Number of subjects: 126
Study 29235564 — intervention group
Group type: COMPARATOR
Intervention: Moderate risk (PD, cN0/N1, stage cI/II or WMD without IC)
Number of subjects: 126
Study 29235564 — intervention group
Group type: COMPARATOR
Intervention: Low risk (WMD with IC)
Number of subjects: 126
Study 27388866 — intervention group
Group type: EXPERIMENTAL
Intervention: Teledebriefing
Number of subjects: 246
Study 27388866 — intervention group
Group type: COMPARATOR
Intervention: On-site debriefing
Number of subjects: 246
Study 26176036 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transhepatic biliary stenting (PTBS)
Number of subjects: 112
Study 26176036 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic biliary stenting (EBS)
Number of subjects: 112
Study 26176036 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 112
Study 22566115 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-minute group (manual placental removal if not spontaneously delivered by 10 minutes)
Number of subjects: 312
Study 22566115 — intervention group
Group type: COMPARATOR
Intervention: 15-minute group (manual placental removal if not spontaneously delivered by 15 minutes)
Number of subjects: 312
Study 20653164 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention enema of the decoction for clearing away heat, expelling dampness, promoting blood circulation and healing ulcer
Number of subjects: 100
Study 20653164 — intervention group
Group type: COMPARATOR
Intervention: Retention enema of the enterosoluble tablet sulfasalazine
Number of subjects: 100
Study 18576354 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CCR2 monoclonal antibody at 0.5 mg/kg
Number of subjects: 32
Study 18576354 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CCR2 monoclonal antibody at 1.5 mg/kg
Number of subjects: 32
Study 18576354 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CCR2 monoclonal antibody at 4.0 mg/kg
Number of subjects: 32
Study 18576354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 15818420 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheme I: tetracycline 500 mg qid, furazolidone 100 mg qid, colloidal bismuth subcitrate 120 mg qid for 3 days
Number of subjects: 66
Study 15818420 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheme II: tetracycline 500 mg qid, furazolidone 100 mg qid, colloidal bismuth subcitrate 120 mg qid for 4 days
Number of subjects: 66
Study 15818420 — intervention group
Group type: EXPERIMENTAL
Intervention: Both schemes (I and II)
Number of subjects: 66
Study 15818420 — intervention group
Group type: EXPERIMENTAL
Intervention: Hp eradication
Number of subjects: 66
Study 15818420 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (both schemes)
Number of subjects: 66
Study 11922194 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulphate
Number of subjects: 212
Study 11922194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 10069677 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh; 50 microg)
Number of subjects: 20
Study 10069677 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (1 microM for 5 min)
Number of subjects: 20
Study 7549273 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotheissen-McVay method
Number of subjects: 58
Study 7549273 — intervention group
Group type: EXPERIMENTAL
Intervention: Shouldice method
Number of subjects: 58
Study 7549273 — intervention group
Group type: EXPERIMENTAL
Intervention: Marcy method
Number of subjects: 58
Study 7549273 — intervention group
Group type: EXPERIMENTAL
Intervention: Postempsky-Halsted I method
Number of subjects: 58
Study 7549273 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliopubic tract repair
Number of subjects: 58
Study 7549273 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral preperitoneal prosthetic repair
Number of subjects: 58
Study 7549273 — intervention group
Group type: EXPERIMENTAL
Intervention: Bassini's method
Number of subjects: 58
Study 7549273 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 men who had not undergone surgery)
Number of subjects: 58
Study 2035858 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of preservative-free morphine in 1.0 mL of 0.9% saline added to local anesthetic solution (20 mL of 1% plain lignocaine, 20 mL of 0.5% plain bupivacaine) with intramuscular placebo injection of 1.0 mL of 0.9% saline
Number of subjects: 50
Study 2035858 — intervention group
Group type: COMPARATOR
Intervention: 1.0 mL of 0.9% saline added to local anesthetic solution with intramuscular injection of 5 mg of preservative-free morphine in 1.0 mL of 0.9% saline
Number of subjects: 50
Study 31646981 — intervention group
Group type: EXPERIMENTAL
Intervention: nal-IRI (mg/m2, 46h infusion)/5-FU (2400 mg/m2, 46h infusion)/leucovorin (400 mg/m2, 0.5h infusion) d1 on 14 day-cycles
Number of subjects: 92
Study 31646981 — intervention group
Group type: COMPARATOR
Intervention: cisplatin (25 mg/m2, 1h infusion)/gemcitabine (1000 mg/m2, 0.5h infusion) d1 and d8 on 21 day-cycles
Number of subjects: 92
Study 31646981 — intervention group
Group type: EXPERIMENTAL
Intervention: nal-IRI/5-FU/leucovorin
Number of subjects: 92
Study 31646981 — intervention group
Group type: COMPARATOR
Intervention: cisplatin/gemcitabine
Number of subjects: 92
Study 30261853 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week multimodal intervention including supervised exercise training, home-based walking, supportive nurse-led counseling, and protein supplement after training.
Number of subjects: 100
Study 30261853 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week multimodal intervention
Number of subjects: 100
Study 30261853 — intervention group
Group type: COMPARATOR
Intervention: Standard oncological treatment
Number of subjects: 100
Study 24971674 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral nutrition intervention with a one-week booster added three months post-intervention.
Number of subjects: 107
Study 24971674 — intervention group
Group type: COMPARATOR
Intervention: Control group (no booster added).
Number of subjects: 107
Study 25250415 — intervention group
Group type: EXPERIMENTAL
Intervention: SMILE
Number of subjects: 100
Study 25250415 — intervention group
Group type: COMPARATOR
Intervention: LASIK
Number of subjects: 100
Study 23063049 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based computerized tracking system (CTS)
Number of subjects: 0
Study 23063049 — intervention group
Group type: COMPARATOR
Intervention: Low usage of the CTS
Number of subjects: 0
Study 20663629 — intervention group
Group type: EXPERIMENTAL
Intervention: Verona Coding Definitions of Emotional Sequences (VR‐CoDES)
Number of subjects: 28
Study 17926336 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid tryptophan depletion (RTD)
Number of subjects: 22
Study 17926336 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 22
Study 15749211 — intervention group
Group type: EXPERIMENTAL
Intervention: Costochondral grafts
Number of subjects: 55
Study 12202665 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide and radiotherapy (75 mg/m(2)/d concurrent with 40‐Gy radiotherapy for 4 weeks, followed by 200 mg/m(2)/d for 5 days every 28 days for 6 cycles)
Number of subjects: 52
Study 12202665 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (40‐Gy radiotherapy for 4 weeks)
Number of subjects: 52
Study 12202665 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide and radiotherapy
Number of subjects: 52
Study 12202665 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 52
Study 10362821 — intervention group
Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator (t-PA)
Number of subjects: 624
Study 10362821 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 624
Study 8521160 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based behavioral treatment for children
Number of subjects: 113
Study 8521160 — intervention group
Group type: COMPARATOR
Intervention: Family-based behavioral treatment for parents
Number of subjects: 113
Study 1665181 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg alone
Number of subjects: 24
Study 1665181 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5 mg alone
Number of subjects: 24
Study 1665181 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination tablet of lisinopril and hydrochlorothiazide
Number of subjects: 24
Study 1665181 — intervention group
Group type: EXPERIMENTAL
Intervention: Free combination of lisinopril and hydrochlorothiazide
Number of subjects: 24
Study 1665181 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose combination of lisinopril and hydrochlorothiazide
Number of subjects: 24
Study 7212793 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass with Roux‐en‐Y gastrojejunostomy
Number of subjects: 0
Study 7212793 — intervention group
Group type: COMPARATOR
Intervention: Gastric partitioning procedure
Number of subjects: 0
Study 30737098 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-sided tumors
Number of subjects: 899
Study 30737098 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-sided tumors with wild-type KRAS
Number of subjects: 899
Study 30737098 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-sided tumors with mutant KRAS
Number of subjects: 899
Study 30737098 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal tumors with wild-type KRAS
Number of subjects: 899
Study 30737098 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal tumors
Number of subjects: 899
Study 30737098 — intervention group
Group type: COMPARATOR
Intervention: KRAS status (wild-type vs mutant)
Number of subjects: 899
Study 31847328 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-targeting fortification (PTF) group, n = 25
Number of subjects: 48
Study 31847328 — intervention group
Group type: COMPARATOR
Intervention: Fixed-fortification (FF) group, n = 23
Number of subjects: 48
Study 31847328 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PTF and FF)
Number of subjects: 48
Study 27545051 — intervention group
Group type: EXPERIMENTAL
Intervention: Transosseous repair (TO group)
Number of subjects: 20
Study 27545051 — intervention group
Group type: COMPARATOR
Intervention: Transosseous-equivalent repair (TOE group)
Number of subjects: 20
Study 26377913 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid rotation
Number of subjects: 50
Study 26377913 — intervention group
Group type: COMPARATOR
Intervention: Opioid combination
Number of subjects: 50
Study 23245705 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature-based sounds (N-BS) intervention for 90 minutes using media players and headphones.
Number of subjects: 60
Study 23245705 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo) with no nature-based sounds intervention.
Number of subjects: 60
Study 21391015 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Management Training (Oregon model)
Number of subjects: 112
Study 21391015 — intervention group
Group type: COMPARATOR
Intervention: Control group (active treatment alternative)
Number of subjects: 112
Study 19476015 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 2.5 mg/pseudoephedrine 120 mg (DL/PSE) bid
Number of subjects: 598
Study 19476015 — intervention group
Group type: COMPARATOR
Intervention: Desloratadine 5.0 mg qd
Number of subjects: 598
Study 19476015 — intervention group
Group type: COMPARATOR
Intervention: Pseudoephedrine 120 mg bid
Number of subjects: 598
Study 17179911 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml of 1.5% epidural lidocaine
Number of subjects: 60
Study 17179911 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml of normal saline
Number of subjects: 60
Study 17179911 — intervention group
Group type: COMPARATOR
Intervention: No test solution (Control group)
Number of subjects: 60
Study 14714242 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical carbon‐fibre intervertebral fusion cage (CIFC)
Number of subjects: 103
Study 14714242 — intervention group
Group type: COMPARATOR
Intervention: Cloward procedure (CP)
Number of subjects: 103
Study 14714242 — intervention group
Group type: EXPERIMENTAL
Intervention: CIFC
Number of subjects: 103
Study 14714242 — intervention group
Group type: COMPARATOR
Intervention: CP
Number of subjects: 103
Study 14714242 — intervention group
Group type: EXPERIMENTAL
Intervention: CIFC and CP
Number of subjects: 103
Study 12234896 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% O(2)
Number of subjects: 12
Study 12234896 — intervention group
Group type: EXPERIMENTAL
Intervention: 97.5% O(2) + 2.5% CO(2)
Number of subjects: 12
Study 12234896 — intervention group
Group type: EXPERIMENTAL
Intervention: 95% O(2) + 5% CO(2)
Number of subjects: 12
Study 12234896 — intervention group
Group type: EXPERIMENTAL
Intervention: 92% O(2) + 8% CO(2)
Number of subjects: 12
Study 9852936 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulation at 3 hours
Number of subjects: 874
Study 9852936 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulation at 4 hours
Number of subjects: 874
Study 9852936 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulation at 6 hours
Number of subjects: 874
Study 9852936 — intervention group
Group type: EXPERIMENTAL
Intervention: Late hematoma formation
Number of subjects: 874
Study 9852936 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician variation
Number of subjects: 874
Study 7723267 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment (emergency operation in peritonitis or nonoperative management with cleansing enema, purgatives, and infusion-transfusion therapy)
Number of subjects: 532
Study 7723267 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency colonoscopy and ultrasonic diagnosis with fractional oral treatment using 30% solution of polyethylene oxide-400 and 1% chloramphenicol
Number of subjects: 532
Study 2521934 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (5 mg x2/day for 2 weeks, then 10 mg x2/day)
Number of subjects: 113
Study 2521934 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/day)
Number of subjects: 113
Study 2521934 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 113
Study 2521934 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 113
Study 2521934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 31660826 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic AUC‐based chemotherapy
Number of subjects: 153
Study 31660826 — intervention group
Group type: COMPARATOR
Intervention: BSA guided chemotherapy
Number of subjects: 153
Study 30511130 — intervention group
Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene suture buttress-reinforced pancreaticojejunostomy (PBRP)
Number of subjects: 0
Study 30511130 — intervention group
Group type: COMPARATOR
Intervention: Traditional pancreaticojejunostomy (TP)
Number of subjects: 0
Study 30511130 — intervention group
Group type: EXPERIMENTAL
Intervention: PBRP
Number of subjects: 0
Study 30511130 — intervention group
Group type: COMPARATOR
Intervention: TP
Number of subjects: 0
Study 29025830 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus SCT education (SCT)
Number of subjects: 65
Study 29025830 — intervention group
Group type: COMPARATOR
Intervention: Exercise plus attention control education (CON)
Number of subjects: 65
Study 25927504 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load strength training
Number of subjects: 58
Study 25927504 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 58
Study 23390210 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Epilepsy Educational System (MEES) with text messages
Number of subjects: 136
Study 23390210 — intervention group
Group type: COMPARATOR
Intervention: Printed epilepsy educational material
Number of subjects: 136
Study 22586631 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16/18 vaccine
Number of subjects: 7466
Study 19326811 — intervention group
Group type: EXPERIMENTAL
Intervention: Piper longum (15 mg)
Number of subjects: 32
Study 19326811 — intervention group
Group type: EXPERIMENTAL
Intervention: Piper longum (30 mg)
Number of subjects: 32
Study 19326811 — intervention group
Group type: COMPARATOR
Intervention: Dextrin placebo
Number of subjects: 32
Study 16377058 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial ventilation performed in isolation
Number of subjects: 36
Study 16377058 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR alone
Number of subjects: 36
Study 16377058 — intervention group
Group type: COMPARATOR
Intervention: CPR and CPR+AED
Number of subjects: 36
Study 15298338 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir/insulin aspart
Number of subjects: 595
Study 11515348 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole suspension (30 mg via nasogastric tube)
Number of subjects: 36
Study 11515348 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole intact capsule (30 mg orally)
Number of subjects: 36
Study 11515348 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole suspension
Number of subjects: 36
Study 11515348 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole intact capsule
Number of subjects: 36
Study 11515348 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole suspension and intact capsule
Number of subjects: 36
Study 10351117 — intervention group
Group type: COMPARATOR
Intervention: LW 50020 (Luivac; Paspat oral), taken once daily for two periods of 4 weeks each, with a treatment-free interval of 4 weeks.
Number of subjects: 0
Study 7845560 — intervention group
Group type: EXPERIMENTAL
Intervention: Internally-controlled orienting using central informative cues
Number of subjects: 0
Study 7845560 — intervention group
Group type: EXPERIMENTAL
Intervention: Externally-controlled orienting using peripheral non-informative cues
Number of subjects: 0
Study 7845560 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of altitudinal neglect
Number of subjects: 0
Study 3394768 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection in upper eyelids
Number of subjects: 26
Study 3394768 — intervention group
Group type: COMPARATOR
Intervention: Saline injection in lower eyelids
Number of subjects: 26
Study 30630800 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine (DEX)
Number of subjects: 92
Study 27234929 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 500
Study 27234929 — intervention group
Group type: COMPARATOR
Intervention: Manual Small-Incision Cataract Surgery (MSICS)
Number of subjects: 500
Study 27234929 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline IOP
Number of subjects: 500
Study 27234929 — intervention group
Group type: EXPERIMENTAL
Intervention: AOD500 widening
Number of subjects: 500
Study 27234929 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline AOD500
Number of subjects: 500
Study 27234929 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline anterior chamber depth
Number of subjects: 500
Study 25257686 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental AmF/SnF2 mouth rinse A
Number of subjects: 28
Study 25257686 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental AmF/SnF2 mouth rinse B
Number of subjects: 28
Study 25257686 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental AmF/SnF2 mouth rinse C
Number of subjects: 28
Study 25257686 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenolic/essential oil rinse D
Number of subjects: 28
Study 25257686 — intervention group
Group type: COMPARATOR
Intervention: Water control E
Number of subjects: 28